Sandostatin^® LAR^® GEP NETs Virtual Booth

Sandostatin LAR Virtual Booth matches your experience to that of attendees at international scientific congresses.

Move your mouse below for more information: Enter by clicking on the numbered exhibit panels or the titles listed below the Booth.

1. Evidence: Proven long-term efficacy in the control of symptoms and tumour activity.^1-4
2. Efficacy: Sandostatin LAR has proven control over debilitating symptoms, including diarrhoea and flushing.^3,5
3. Safety: Sandostatin LAR is well tolerated with an established safety profile ^3,4
4. Experience: Most prescribed somatostatin analogue in the world.^6,7
5. Convenience: The Home Administration Programme* provides easier access to treatment.
6. Power to Treat: Sandostatin LAR provides effective symptom relief via control of bioactive substances.⁴

* Programme may not be available in all countries. Please consult your local Novartis representative in your respective countries.

References: 1. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in
malignant carcinoid syndrome. J Clin Oncol. 1999;17:600-606. 2. Arnold R, Trautmann ME, Creutzfeldt W, et al; and the German Sandostatin Multicentre Study Group. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996;38:430-438. 3. Data on file, Novartis Pharma AG. 4. Sandostatin LAR Basic Prescribing Information, Novartis Pharma AG. 5. Anthony L, Freda PU. From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin. 2009;25:2989-2999. 6. Verispan's IMS Report to Novartis Pharma AG; 2007. 7. IMS Health Midas Sales (PADDS). December 2007